Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

被引：0
|
作者：
Anne Bertrand
Marie Kostine
Thomas Barnetche
Marie-Elise Truchetet
Thierry Schaeverbeke
机构：
[1] Département de Rhumatologie,Laboratoire d’Immunologie, UMR
[2] Hôpital Pellegrin,CNRS 5164
[3] CHU de Bordeaux,Unité sous Contrat, Infections à Mycoplasmes et à Chlamydia chez l’Homme
[4] Université de Bordeaux,undefined
[5] Université de Bordeaux,undefined
来源：
BMC Medicine | / 13卷
关键词：
Anti-CTLA4 antibodies; Colitis; Dermatitis; Hypohysitis; Immune related adverse events; Ipilimumab; Metastatic tumors; Oncology; Tremelimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies
    Amoroso, V.
    Gallo, F.
    Alberti, A.
    Paloschi, D.
    Bravo, W. Ferrari
    Esposito, A.
    Cosentini, D.
    Grisanti, S.
    Pedersini, R.
    Petrelli, F.
    Berruti, A.
    ESMO OPEN, 2023, 8 (02)
  • [32] Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis
    Guzman-Prado, Yuli
    Ben Shimol, Jennifer
    Samson, Ondrej
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (01) : 89 - 100
  • [33] Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis
    Yuli Guzman-Prado
    Jennifer Ben Shimol
    Ondrej Samson
    Cancer Immunology, Immunotherapy, 2021, 70 : 89 - 100
  • [34] Colitis induced by immune checkpoint inhibitors: Anti-CTLA-4 antibodies and anti-PD-1/PDL-1 antibodies
    Vozy, A.
    Coutzac, C.
    ONCOLOGIE, 2016, 18 (9-10) : 501 - 508
  • [35] Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis
    Hou, Yan-Li
    Wang, Di-Ya
    Hu, Jie-Xuan
    Tian, Ru-Yue
    Wang, Wei
    Su, Qiang
    Li, Hongyang
    Wang, Yan-Ling
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2022, 30 (06) : 1449 - 1459
  • [36] Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
    Wang, Peng-Fei
    Chen, Yang
    Song, Si-Ying
    Wang, Ting-Jian
    Ji, Wen-Jun
    Li, Shou-Wei
    Liu, Ning
    Yan, Chang-Xiang
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [37] Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry
    Sun, Michel M.
    Kelly, Scott P.
    Mylavarapu, Apoorva L.
    Holland, Gary N.
    Coleman, Anne L.
    Yu, Fei
    Hsu, Stephen
    Lum, Flora
    Gordon, Lynn K.
    OPHTHALMOLOGY, 2021, 128 (06) : 910 - 919
  • [38] Immune-related adverse events associated with first-line immune checkpoint inhibitors for metastatic renal cell carcinoma: A systematic review and network meta-analysis
    Wang, Shan
    Lv, Hongwei
    Yu, Jing
    Chen, Miao
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 131
  • [39] Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
    El Osta, B.
    Hu, F.
    Sadek, R.
    Chintalapally, R.
    Tang, S. -C.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 119 : 1 - 12
  • [40] Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis
    Kou, Liqiu
    Wen, Qinglian
    Xie, Xiaolu
    Chen, Xiu
    Li, Jun
    Li, Yaling
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345